Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway - researchr publication

researchr

You are not signed in
Sign in
Sign up

Mateo Aboy, Cristina Crespo, Ariel Stern. Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway. npj Digit. Medicine, 7(1), 2024. [doi]

Abstract is missing.

runs on WebDSL